NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VTVT
vTv Therapeutics Inc.
There isn't enough reported data to score VTVT yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VTVT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
VTVT's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | โ |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VTVT PE Valuation
VTVT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VTVT Forward outlook
There aren't enough analyst estimates for VTVT to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over VTVT on earnings quality, reporting a profit while its opponent remains loss making.
VTVT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.11 | +$3.09 |
| Q1 2026 | $0.02 | +$3.11 |
| Q4 2025 | -$3.62 | -$0.13 |
| Q3 2025 | -$3.40 | +$1.13 |
| Q2 2025 | -$3.20 | +$3.72 |
| Q1 2025 | -$3.09 | +$5.78 |
| Q4 2024 | -$3.49 | +$6.42 |
| Q3 2024 | -$4.53 | +$6.04 |
VTVT lost $0.11 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over VTVT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
VTVT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $9K | 0% |
| Q2 2022 | $9K | 0% |
| Q1 2022 | $2M | +103% |
| Q4 2021 | $9K | -100% |
| Q3 2021 | $3M | +42757% |
| Q1 2021 | $987K | +12238% |
| Q4 2020 | $6.4M | +91314% |
VTVT's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | 63% | N/A |
| Q4 2024 | -28776% | N/A |
| Q1 2024 | -563% | N/A |
| Q4 2022 | -70478% | +52956 points |
| Q2 2022 | -44744% | +7144 points |
| Q1 2022 | -324% | +110 points |
| Q4 2021 | -123433% | -123462 points |
| Q3 2021 | -53% | +40404 points |
VTVT has the edge over NVO on profitability, with a higher operating margin.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over VTVT on cash generation, producing positive trailing cash flow while its opponent burns cash.
VTVT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.2M | -$5M |
| Q2 2026 | -$11.4M | -$6.3M |
| Q1 2026 | $9.2M | +$14.8M |
| Q4 2025 | -$9.3M | -$4.4M |
| Q3 2025 | -$5.2M | +$1.2M |
| Q2 2025 | -$5.1M | +$1.6M |
| Q1 2025 | -$5.7M | +$1.6M |
| Q4 2024 | -$4.8M | -$1.9M |
VTVT has burned cash in almost every quarter: โ$22M over the past year, against โ$21M the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
VTVT Net Leverage
VTVT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VTVT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 3.6 | Oversold |
VTVT's weekly RSI is 31 (neutral) and its Stochastic is 4 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over VTVT on valuation relative to its sector.
VTVT PE vs Healthcare Sector
| Metric | VTVT | Sector median | Relative |
|---|---|---|---|
| PE | 1,559x | 26x | 5,931% above |
| PE % | 19 | 29 | 10 pts below |
VTVT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over VTVT on trend strength, trading above more of its moving averages.
VTVT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.4 | 22% below |
| 20 week MA | $30.2 | 31% below |
| 50 week MA | $33.0 | 37% below |
| 100 week MA | $25.8 | 20% below |
| 200 week MA | $23.5 | 12% below |
VTVT is in a downtrend: it's below all five of its weekly moving averages, and 12% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over VTVT on returns for 2026, with the stronger performance.
VTVT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $71.6 | $82.0 | +15% |
| 2021 | $82.0 | $43.2 | -47% |
| 2022 | $43.2 | $27.2 | -37% |
| 2023 | $27.2 | $11.5 | -58% |
| 2024 | $11.5 | $13.2 | +15% |
| 2025 | $13.2 | $37.9 | +187% |
| 2026 YTD | $37.9 | $20.7 | -45% |
VTVT's yearly returns have swung widely, from +187% in 2025 to โ58% in 2023. It's down 45% so far in 2026.